References
- Balandrin MF, Klocke JA, Wurtele ES, Bollinger WH. (1985): Natural plant chemicals: Sources of industrial and medicinal materials. Science 228: 1154–1160.
- Beck-Sagué CM, Jarvis WR. (1993): Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167: 1247–1251.
- Brol CG, Cotton L, Samayoa B, Paz L, Samayoa CA, Quattrini E, Gonzalez M, Velasquez-Porta T, Arathoon E. (2002): Cryptococcus neoformans infections in persons living with HIV/AIDS that attend to urban hospitalary clinic. In: Proceedings of the International Conference on AIDS 2002, July 7–12 (14: (abstract no. B10259).
- Cos P, Vlietinck AJ, Berghe DV, Maes L. (2006): Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’. J Ethnopharmacol 106: 290–302.
- Diamond RD. (1991): The growing problem of mycoses in patients infested with human immunodeficiency virus. Rev Infect Dis 13: 480–486.
- Eloff JN. (1998a): A sensitive and quick microplate method to determine the minimum inhibitory concentration of plant extracts for bacteria. Planta Med 64: 711–713.
- Eloff JN. (1998b): Which extractant should be used for the screening and isolation of antimicrobial components from plants? J Ethnopharmacol 60: 1–8.
- Eloff JN. (2000): A proposal on expressing the antibacterial activity of plant extracts – a small first step in applying scientific knowledge to rural primary health care in South Africa. S Afr J Sci 96: 116–118.
- Eloff JN. (2004): Quantification of the bioactivity of plant extracts during screening and bioassay guided fractionation. Phytomedicine 11: 370–371.
- Gearhart MO. (1994): Worsening of lung infection with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 28: 1177–1181.
- Ghannoum MA, Rice LB. (1999): Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501–517.
- Goa KL, Barradell LB. (1995): Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.
- Kotzé M, Eloff JN. (2002): Extraction of antibacterial compounds from Combretum microphyllum (Combretaceae). S Afr J Bot 68: 62–67.
- Lazar JD, Wilner KD. (1990): Drug interactions with fluconazole. Rev Infect Dis 12: 327–333.
- Masoko P, Picard J, Eloff JN. (2005): Antifungal activities of six South African Terminalia species (Combretaceae). J Ethnopharmacol 99: 301–308.
- Masoko P, Eloff JN. (2006): Bioautography indicates the multiplicity of antifungal compounds from twenty-four southern African Combretum species (Combretaceae). Afr J Biotechnol 5: 1625–1647.
- McGaw LJ, Rabe T, Sparg SG, Jager AK, Eloff JN, van Staden J. (2001): An investigation on the biological activity of Combretum species. J Ethnopharmacol 75: 45–50.
- Nostro A, Germanò MP, Angelo VD, Marino A, Cannatelli MA. (2000): Extraction methods and bioautography for evaluation of medicinal plant antimicrobial activity. Lett Appl Microbiol 30: 379–384.
- Powderly WG. (1993): Cryptococcal meningitis and AIDS. Clin Infect Dis 17: 837–842.
- Saral R. (1991): Candida and Aspergillus infection in immunocompromised patients: an overview. Rev Infect Dis 13: 487–492.
- Uicker WC, Doyle HA, James PM, Langlois M, Buchanan KL. (2005): Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol 43: 27–38.
- Van Wyk B-E, van Oudtshoorn B, Gericke N. (1997): Medicinal Plants of South Africa. Pretoria, Briza Publications, p. 10.